Novi Yanti Sari: When MPNs Affect the Heart
Novi Yanti Sari, Lecturer at Universitas Pelita Harapan, shared a post on LinkedIn about a recent article by Orly Leiva et al, published in Journal of the American College of Cardiology, adding:
”Beyond thrombosis: what cardiovascular complications should we look for in patients with MPN?
This review highlights that the CV burden extends beyond arterial & venous thrombosis:
- HF may be more prevalent in MPNs than in general population, with worse HF-specific outcomes reported in myelofibrosis
- Traditional CV risk factors are less common in these patients, suggesting a distinct HF phenotype PH is common and may be pre-capillary, post-capillary or combined, requiring careful haemodynamic evaluation. Echo First is the recommended screening tool, with RHC for definitive diagnosis
- PH screening should be considered in patients with myelofibrosis, long-standing MPN, signs of disease progression and cardiomegaly Emerging data suggest that both HF and PH may be associated with adverse cardiovascular outcomes and hematologic progression in MPN, highlighting potential shared pathophysiology such as chronic inflammation and JAK/STAT pathway activation.”
Title: Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review
Authors: Orly Leiva, Olivia Liu, Anthony Kanelidis, Stanley Swat, Leo Gozdecki, Mark Belkin, Jonathan Grinstein, Sara Kalantari, Gene Kim, Jeanne DeCara, Ben Chung, Anand Patel, Olatoyosi Odenike, Eric H. Yang, Michelle Bloom, Jose Alvarez-Cardona, Joan How, Gabriela Hobbs.
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM